<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Metabolic Research on What is a GLP-1 Patch? | Comprehensive Guide &amp; Insights</title>
		<link>https://5485.22887.cc/tags/metabolic-research/</link>
		<description>Recent content in Metabolic Research on What is a GLP-1 Patch? | Comprehensive Guide &amp; Insights</description>
		<generator>Hugo</generator>
		<language>en-US</language>
		
		
		
		
			<lastBuildDate>Wed, 24 Aug 2022 09:20:09 -0500</lastBuildDate>
		
			<atom:link href="https://5485.22887.cc/tags/metabolic-research/index.xml" rel="self" type="application/rss+xml" />
			<item>
				<title>What Is DLP1: The Overlooked Peptide in Metabolic Research</title>
				<link>https://5485.22887.cc/posts/what-is-dlp1-the-overlooked-peptide-in-metabolic-research/</link>
				<pubDate>Wed, 24 Aug 2022 09:20:09 -0500</pubDate>
				<guid>https://5485.22887.cc/posts/what-is-dlp1-the-overlooked-peptide-in-metabolic-research/</guid>
				<description>&lt;p&gt;So you typed &amp;ldquo;what is DLP1&amp;rdquo; and got a mix of cryptic research papers and forum posts — I&amp;rsquo;ve been there. Here&amp;rsquo;s the plain-talk answer: DLP1 (dipeptidyl peptidase-like protein 1, or sometimes referred to as DPP1 in early literature) is a lesser-known peptide that shares structural similarities with GLP-1 but acts through a distinct pathway. While GLP-1 has dominated headlines for weight loss and diabetes, DLP1 is quietly gaining attention for its potential role in fine-tuning insulin release and modulating gut-brain signaling, without the nausea that often accompanies traditional GLP-1 therapies. In clinical pipelines, DLP1 is still largely preclinical, but several biotech firms are exploring whether it could become an adjunct or alternative to existing incretin-based drugs.&lt;/p&gt;</description>
			</item>
	</channel>
</rss>
